tbuckley/cabot-search huggingface dataset:
A commentary on “Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study”
Authors: Jia Luo, Qian Yang, Wen Ma, Hua Fan
Journal: International Journal of Surgery (2024)

Department of Oncology and Hematology, People's Hospital of Leshan, Leshan, 614000, Sichuan Province, China Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding Author Address: Department of Oncology and Hematology, People's Hospital of Leshan, No. 238, Baita Street, Shizhong District, Leshan, 614000, Sichuan Province, China. Tel: +86 15892925098. E-mail address: [email protected] (J. Luo). This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Authors: Gerald W. Smetana, Giulio R. Romeo, Sylvia E. Rosas, Risa B. Burns
Journal: Annals of Internal Medicine (2024)

Nearly 15% of U.S. adults have diabetes; type 2 diabetes (T2D) accounts for more than 90% of cases. Approximately one third of all patients with diabetes will develop chronic kidney disease (CKD). All patients with T2D should be screened annually for CKD with both a urine albumin-creatinine ratio and an estimated glomerular filtration rate. Research into strategies to slow the worsening of CKD and reduce renal and cardiovascular morbidity in patients with T2D and CKD has evolved substantially. In 2022, a consensus statement from the American Diabetes Association and the Kidney Disease: Improving Global Outcomes recommended prioritizing the use of sodium-glucose cotransporter-2 inhibitors and metformin and included guidance for add-on therapy with glucagon-like peptide 1 receptors agonists for most patients whose first-line therapy failed. It also recommended nonsteroidal mineralocorticoid receptor antagonists for patients with hypertension that is not adequately controlled with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers. Here, an endocrinologist and a nephrologist discuss the care of patients with T2D and CKD and how they would apply the consensus statement to the care of an individual patient with T2D who is unaware that he has CKD.
The Effect of Heat Exposure on Myocardial Blood Flow and Cardiovascular Function
Authors: Hadiatou Barry, Josep Iglesies-Grau, Georgia K. Chaseling, Jade Paul, Camila Gosselin, Caroline D’Oliviera-Sousa, Martin Juneau, Francois Harel, David Kaiser, Matthieu Pelletier-Galarneau, Daniel Gagnon
Journal: Annals of Internal Medicine (2024)

Heat extremes are associated with greater risk for cardiovascular death. The pathophysiologic mechanisms mediating this association are unknown.
Regarding the evaluation of large language models in breast cancer clinical scenarios
Authors: Rongkang Li, Lei Peng, Rui Liang, Anguo Zhao, Jianye Zhong, Shaohua Zhang
Journal: International Journal of Surgery (2024)

Li, Rongkang; Peng, Lei; Liang, Rui; Zhao, Anguo; Zhong, Jianye; Zhang, Shaohua PhD Author Information
A commentary on “the transition of surgical simulation training and its learning curve: a bibliometric analysis from 2000 to 2023” (Int J Surg. 2024 May 9.)
Authors: Jinming Liu, Guolin Zhang, Biao Zhang, Dong Shang
Journal: International Journal of Surgery (2024)

aPancreas & Biliary Center, Department of General Surgery, Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China bDepartment of Cardiology, The Second Hospital of Dalian Medical University, Dalian, China cInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian, China These authors have contributed equally to this work: Jinming Liu, Guolin Zhang Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Pancreas & Biliary Center, Department of General Surgery, Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian China. E-mail address: [email protected] (B. Zhang) *Corresponding author. Address: Pancreas & Biliary Center, Department of General Surgery, Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China. E-mail address: [email protected] (D. Shang). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Bio‐Inspired Micro‐ and Nano‐Scale Surface Features Produced by Femtosecond Laser‐Texturing Enhance TiZr‐Implant Osseointegration
Authors: William Arthur Lackington, Benjamin Bellon, Stefanie Guimond, Peter Schweizer, Claudia Cancellieri, Antoine Ambeza, Anne‐Lise Chopard‐Lallier, Benjamin Pippenger, Andac Armutlulu, Xavier Maeder, Patrik Schmutz, Markus Rottmar
Journal: Advanced Healthcare Materials (2024)

Surface design plays a critical role in determining the integration of dental implants with bone tissue. Femtosecond laser-texturing has emerged as a breakthrough technology offering excellent uniformity and reproducibility in implant surface features. However, when compared to state-of-the-art sandblasted and acid-etched surfaces, laser-textured surface designs typically underperform in terms of osseointegration. This study investigates the capacity of a bio-inspired femtosecond laser-textured surface design to enhance osseointegration compared to state-of-the-art sandblasted & acid-etched surfaces. Laser-texturing facilitates the production of an organized trabeculae-like microarchitecture with superimposed nano-scale laser-induced periodic surface structures on both 2D and 3D samples of titanium-zirconium-alloy. Following a boiling treatment to modify the surface chemistry, improving wettability to a contact angle of 10°, laser-textured surfaces enhance fibrin network formation when in contact with human whole blood, comparable to state-of-the-art surfaces. In vitro experiments demonstrate that laser-textured surfaces significantly outperform state-of-the-art surfaces with a 2.5-fold higher level of mineralization by bone progenitor cells after 28 days of culture. Furthermore, in vivo evaluations reveal superior biomechanical integration of laser-textured surfaces after 28 days of implantation. Notably, during abiological pull-out tests, laser-textured surfaces exhibit comparable performance, suggesting that the observed enhanced osseointegration is primarily driven by the biological response to the surface.
Reply to the commentary on ‘Safety and efficacy of enhanced recovery after surgery among patients undergoing percutaneous nephrolithotomy: a systematic review and meta-analysis’
Authors: Liang Liu, Yong Suo, Yu Xiao, Lin An, Xiao Yue, Ji Zheng, Qiang Wang
Journal: International Journal of Surgery (2024)

Liu, Liang; Suo, Yong; Xiao, Yu; An, Lin; Yue, Xiao; Zheng, Ji; Wang, Qiang Author Information
COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response
Authors: Ethan G. Dutcher, Elissa S. Epel, Ashley E. Mason, Frederick M. Hecht, James E. Robinson, Stacy S. Drury, Aric A. Prather
Journal: Annals of Internal Medicine (2024)

Concern about side effects is a common reason for SARS-CoV-2 vaccine hesitancy.
MethylGenotyper: Accurate Estimation of SNP Genotypes and Genetic Relatedness from DNA Methylation Data
Authors: Yi Jiang, Minghan Qu, Minghui Jiang, Xuan Jiang, Shane Fernandez, Tenielle Porter, Simon M Laws, Colin L Masters, Huan Guo, Shanshan Cheng, Chaolong Wang
Journal: Genomics Proteomics & Bioinformatics (2024)

Abstract Epigenome-wide association studies (EWAS) are susceptible to widespread confounding caused by population structure and genetic relatedness. Nevertheless, kinship estimation is challenging in EWAS without genotyping data. Here, we proposed MethylGenotyper, a method that for the first time enables accurate genotyping at thousands of single nucleotide polymorphisms (SNPs) directly from commercial DNA methylation microarrays. We modeled the intensities of methylation probes near SNPs with a mixture of three beta distributions corresponding to different genotypes and estimated parameters with an expectation-maximization algorithm. We conducted extensive simulations to demonstrate the performance of the method. When applying MethylGenotyper to the Infinium EPIC array data of 4662 Chinese samples, we obtained genotypes at 4319 SNPs with a concordance rate of 98.26%, enabling the identification of 255 pairs of close relatedness. Furthermore, we showed that MethylGenotyper allows for the estimation of both population structure and cryptic relatedness among 702 Australians of diverse ancestry. We also implemented MethylGenotyper in a publicly available R package (https://github.com/Yi-Jiang/MethylGenotyper) to facilitate future large-scale EWAS.
Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.
Authors: Makenzi Colleen Evangelist, James Edward Butrynski, John C. Paschold, Patrick J. Ward, David Michael Waterhouse, Alexander I. Spira, Kashif Ali, David Hakimian, Robert M. Jotte, Timothy Larson, Michael W. Meshad, Rami Owera, Donald A. Richards, Marcus A. Neubauer, Nicholas J Robert, Jennifer L. Yori, Manoj Pant, Robert L. Coleman, David R. Spigel
Journal: Journal of Clinical Oncology (2024)

8047 Background: The Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium (MYLUNG) program seeks to identify and resolve barriers to biomarker testing in patients (pts) with non-small-cell lung cancer (NSCLC). We previously reported prospectively collected molecular testing data in pts with Stage IB-IV NSCLC (Evangelist et al. 2023). Herein we report additional data on molecular testing rates and patterns in the cohort of pts with early-stage (ES) NSCLC. Methods: Pts were enrolled from 12/20-9/22 at 18 community practices (76 sites) across the US Oncology Network. Analyses performed in the ES cohort include rates of molecular testing for targets with approved (PD-L1 , EGFR) or emerging ( ALK) therapies for ES NSCLC and next-generation sequencing (NGS); reasons for not testing; and treatment (Tx) received, including targeted therapy and immunotherapy (IO). Analyses are preliminary as data collection continues over 5-year follow-up. Results: Included in this analysis were 284 pts with newly diagnosed Stage IB-IIIA NSCLC: median age 68y (range 32, 92); 50% female; 54% ECOG 0-1; 61% adenocarcinoma, 36% squamous cell carcinoma. In total, 76% of pts (82% of pts with adenocarcinoma vs 67% with squamous cell carcinoma) had molecular testing ordered prior to or within 12 weeks of initiating first systemic therapy. Rates of testing (either alone or inclusive of other tests) were PD-L1 ,74%; EGFR,71%; ALK, 62%; EGFR + PD-L1, 61%. In total, 52% of pts had NGS testing; overall, 16% received no molecular testing. The most common reasons for not testing were patient and/or provider attitude/perception (34%) and insufficient tumor tissue (25%). Conclusions: New therapeutic options provide a catalyst to increase molecular testing in ES NSCLC. EGFR and PD-L1 testing are now standard for the management of these pts, with other biomarkers emerging. In this study, 54% of pts received testing for PD-L1, EGFR, and ALK, with additional therapy being offered in pts with biomarker-positive tumors; however, 16% still received no molecular testing at all. For pts with EGFRwt/PD-L1+ tumors, prescription of IO increased 1.8-fold post-adjuvant FDA approval. Data from this and future analyses will be used to implement interventions to improve molecular testing rates in NSCLC. [Table: see text]
A Review of Conductive Hydrogel‐Based Wearable Temperature Sensors
Authors: Fan Mo, Pengcheng Zhou, Shihong Lin, Junwen Zhong, Yan Wang
Journal: Advanced Healthcare Materials (2024)

Conductive hydrogel has garnered significant attention as an emergent candidate for diverse wearable sensors, owing to its remarkable and tailorable properties such as flexibility, biocompatibility, and strong electrical conductivity. These attributes make it highly suitable for various wearable sensor applications (e.g., biophysical, bioelectrical, and biochemical sensors) that can monitor human health conditions and provide timely interventions. Among these applications, conductive hydrogel-based wearable temperature sensors are especially important for healthcare and disease surveillance. This review aims to provide a comprehensive overview of conductive hydrogel-based wearable temperature sensors. First, this work summarizes different types of conductive fillers-based hydrogel, highlighting their recent developments and advantages as wearable temperature sensors. Next, this work discusses the sensing characteristics of conductive hydrogel-based wearable temperature sensors, focusing on sensitivity, dynamic stability, stretchability, and signal output. Then, state-of-the-art applications are introduced, ranging from body temperature detection and wound temperature detection to disease monitoring. Finally, this work identifies the remaining challenges and prospects facing this field. By addressing these challenges with potential solutions, this review hopes to shed some light on future research and innovations in this promising field.
Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).
Authors: Charu Aggarwal, Alex Martinez-Marti, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy S. Chu, Isabelle Monnet, Alfredo Sanchez, Shaker R. Dakhil, David Ross Camidge, Marine Pillet, Miranda Brown, Adam Dowson, Zachary A. Cooper, Rakesh Kumar, Roy S. Herbst
Journal: Journal of Clinical Oncology (2024)

8046 Background: D consolidation after concurrent chemoradiotherapy (cCRT) improves survival in pts with uNSCLC. Rational immunotherapy combinations may further improve outcomes. As radiotherapy can induce expression of CD73, HLA-E (NKG2A ligand), and PD-L1 in tumor cells, all of which suppress antitumor immunity, there is a rationale for blockade of these immune checkpoints after cCRT. Interim results from COAST (NCT03822351), a global, open-label, Phase 2 study of D ± M (anti-NKG2A) or O (anti-CD73) as consolidation therapy in pts with Stage III uNSCLC, suggested improved progression free survival (PFS) with D+O and D+M vs D alone. We present updated efficacy and safety. Methods: Pts with histologically / cytologically documented Stage III uNSCLC and ECOG PS 0 / 1 with no progression after cCRT were randomized (1:1:1; stratified by histology) within 42 days post cCRT to receive D 1500 mg IV every 4 weeks (Q4W) for 12 months ± O 3000 mg IV Q2W for two cycles then Q4W or M 750 mg IV Q2W. Primary endpoint: objective response rate (ORR). Key secondary endpoints: safety, PFS, and overall survival (OS). Results: From Jan 2019 to Jul 2020, 186 of 189 randomized pts received treatment. Baseline characteristics were generally balanced across arms. As of Jul 18, 2023, median follow-up was 30.1 mo (range, 0.4–48.9). Of pts receiving D, D+O, and D+M, 69.7%, 44.1%, and 41.0% discontinued treatment (Tx), primarily due to progressive disease (42.4%, 18.7%, and 19.6%) or adverse events (AEs; 15.2%, 15.3%, and 14.8%). Median exposure was 7 cycles (range, 1–13) for D, and 13 (1–13) for D+O and D+M. ORR, PFS, and OS (39.6% maturity) are summarized in the Table. Tx-emergent AEs occurred in 98.5%, 96.6%, and 100% (Grade [G] 3/4: 34.8%, 33.9%, and 32.8%) of pts receiving D, D+O, or D+M, respectively; immune-mediated AEs (imAEs) occurred in 34.8%, 25.4%, and 34.4% (G 3/4: 3.0%, 0%, and 3.3%); and the AE of special interest pneumonitis occurred in 16.7%, 20.3%, and 18.0% (G 3/4: 0%, 0%, and 1.6%). Subgroup analyses and biomarker data will be presented. Conclusions: D+O and D+M increased ORR and prolonged PFS and OS vs D alone. Safety was similar across arms, with no new safety signals. Further investigation of D, D+O, and D+M in this population is ongoing in the Phase 3 PACIFIC-9 study (NCT05221840). Clinical trial information: NCT03822351 . [Table: see text]
Clinicopathologic and molecular landscape of invasive mucinous adenocarcinoma of the lung.
Authors: Hye Sung Kim, Adam Joseph Dugan, Jen Godden, Calvin Y. Chao, Young Kwang Chae
Journal: Journal of Clinical Oncology (2024)

8037 Background: Invasive mucinous adenocarcinoma (IMA), accounting for 2–10% of lung adenocarcinomas, often mimics pneumonia with multicentric opacities in multiple lobes and both lungs. Notable for its microscopic skip lesions leading to tumor spread through air spaces (STAS), IMA is still under-researched in terms of its comprehensive clinical and genetic characteristics in large, multicenter studies. Methods: Primary lung cancer cases were obtained from the Tempus database, categorized into either IMA or non-IMA, and compared by patient, clinical, biopsy, and molecular characteristics. The normalization of RNA-seq data involved computing transcripts per million (TPM), performing log2 transformations, and adjusting for assay and batch effects. Significantly up- and down-regulated genes were defined as false discovery rate q-values &lt; 0.05 and |log2(fold change)| &gt; 0.5. Results: The study analyzed 18,857 cases, with 655 (3.5%) in the IMA group and 18,202 (96.5%) in the non-IMA group. The IMA group predominantly consisted of older individuals (median age 70 vs. 68; p&lt;0.001), had fewer smokers (63% vs. 73%; p&lt;0.001), and included more individuals of Hispanic or Latino ethnicity (4.3% vs. 2.7%; p=0.007). This group was more likely to be diagnosed with early-stage cancer and less likely to have stage 4 cancer at diagnosis (stage 1: 23% vs. 14%, stage 2: 18% vs. 7.3%, stage 3: 23% vs. 17%, stage 4: 36% vs. 62%; p&lt;0.001). They exhibited significantly lower tumor mutational and neoantigen burdens (median 3.1 vs. 4.6 mutations/Mb and 6 vs. 9 neoantigens/Mb, respectively; both p&lt;0.001), fewer positive PD-L1 statuses (27% vs. 58%; p&lt;0.001), and different immune cell infiltration patterns (Table). Gene expression analysis revealed 416 upregulated and 258 downregulated genes in the IMA group compared to the non-IMA group. Conclusions: This analysis underscores the unique clinicopathologic and molecular characteristics of IMAs. An improved understanding of IMA’s biological behavior could lead to the development of more effective, personalized treatment strategies. [Table: see text]
Comprehensive analysis of predictive factors for efficacy in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer, utilizing individual patient data from the Japan lung cancer society integrated clinical trial database: Is there room for further improvement?
Authors: Yuichi Ozawa, Kouji Yamamoto, Shunichi Sugawara, Seiji Niho, Yuichiro Ohe, Hiroaki Okamoto, Katsuyuki Hotta, Norihiko Ikeda, Nobuyuki Yamamoto
Journal: Journal of Clinical Oncology (2024)

8043 Background: The standard treatment for unresectable, locally advanced NSCLC is concurrent chemoradiotherapy followed by durvalumab. While the effectiveness of chemoradiotherapy is pivotal, the exploration into predictive factors of the efficacy is notably limited. Methods: The Japanese Lung Cancer Society (JLCS) integrated eight randomized Phase II/III trials (JCOG9812, JCOG0301, NJLCG0601, OLCSG0007, SPECTRA, TORG1018, WJOG5008L, WJTOG0105) concerning chemoradiotherapy for locally advanced NSCLC, constructing the JLCS Integrated Clinical Trial Database (JIDB), with individual data of 1288 patients. This study analyzed 1162 patients who underwent concurrent chemoradiotherapy, focusing on factors impacting PFS. A logistic regression with the least absolute shrinkage and selection operator (LASSO) analyses for 3-yr PFS were performed, and the five most related factors were further evaluated using the Kaplan-Meier method and log-rank tests. The impact of pneumonitis and esophagitis on PFS was also explored. Results: Age [median (Q1;Q3)]; 64 (57;71), male/female; 961/201, Ad/Sq/Oth; 580/446/134, PS 0/1/2; 562/578/5, stage IIIA/IIIB; 468/694, T factor 4/3/2/1/0; 436/158/341/156/3, N factor 3/2/1/0; 300/692/44/62, PS 0/1/2; 562/578/5, primary site; upper, middle/lower lobe; 599/161, BMI; 21.8 (19.7;24.0), weight loss (≥5% within 6m) yes/no; 135/644, LDH (IU/l); 203 (175;276), CRP (mg/dl); 0.70 (0.20;2.60), irradiated dose (Gy); 60 (60;60), combined regimen; platinum/taxane 303, CDDP/mitomycin/vindesine; 254, CDDP/5-FU-based; 196, CDDP/vinorelbine 87, CDDP/pemetrexed 50, others 272. The median PFS in all patients was 9.72m (95% CI; 9.33 – 10.38), with 3-yr, 5-yr, and 10-yr PFS rates of 19.7, 14.3, 10.1%. LASSO logistic regression identified Sq, lower lobe primary, age, pack-years, and weight loss as the top negative influencers. The PFS curve was significantly shorter in patients with lower lobe primary (median of 8.15 vs. 9.46m, p = 0.023) and weight loss (median of 7.29 vs. 9.72m, p &lt; 0.0001). Pneumonitis occurred in 50.9% (grade≥3 in 6.7%) and esophagitis in 41.9% (grade≥3 in 3.9%). Grade≥2 pneumonitis shortened PFS (8.2 vs. 10.2m, p = 0.00015), while, unexpectedly, grade≥1 esophagitis was associated with longer PFS (12.9 vs. 8.6m, p &lt; 0.0001). Conclusions: The efficacy of concurrent chemoradiotherapy varies significantly based on the primary site. Weight loss is a significant predictor of efficacy, as is in metastatic disease. The impact of pneumonitis and esophagitis suggest that modifying lung and esophageal irradiation might enhance treatment efficacy. Further research in this area is still certainly warranted.